Albers G W, Goldberg M P, Choi D W
Department of Neurology, Stanford University Medical Center, CA 94305.
Ann Neurol. 1989 Apr;25(4):398-403. doi: 10.1002/ana.410250412.
Antagonists of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors may offer a new approach for the treatment of ischemic brain injury. This strategy is supported by a well-developed scientific foundation and encouraging results in a variety of in vivo and in vitro experimental models. Several specific antagonists, including MK-801, dextrorphan, dextromethorphan, and ketamine, have already been used at low doses in humans for other indications and are potential candidates for Phase I clinical trials.
N-甲基-D-天冬氨酸（NMDA）亚型谷氨酸受体拮抗剂可能为缺血性脑损伤的治疗提供一种新方法。这一策略有坚实的科学基础支持，并且在多种体内和体外实验模型中都取得了令人鼓舞的结果。几种特定的拮抗剂，包括MK-801、右啡烷、右美沙芬和氯胺酮，已经在人体中以低剂量用于其他适应症，并且是一期临床试验的潜在候选药物。
